Trial Profile
A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Ramucirumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 02 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 01 Aug 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.